lilly attempt cover data risks posed olanzapine zyprexa treatment exposed article new york times lilly published data told sales representatives play conversations doctors shown percent patients taking zyprexa gain pounds year drug patients reported gaining pounds lilly concerned zyprexa sales would hurt company forthright fact drug might cause unmanageable weight gain diabetes according documents cover period snip reassure doctors lilly also publicly said followed patients taken zyprexa clinical trial three years found weight gain appeared plateau nine months company discuss far less reassuring finding early disclosed documents blood sugar levels patients increased steadily three years warning signs emerged documents show four surveys conducted lilly marketing department company found percent psychiatrists polled seen least one patients develop high blood sugar diabetes taking zyprexa compared percent risperdal seroquel lilly never disclosed findings lilly also instructed sales reps downplay medication risks lilly written response documents summary scientific evidence establishing zyprexa causes diabetes also said release documents illegal nice defense deny say documents valid obtained illegally ought make quite legal spectacle another apt quote nyt ways zyprexa documents reminiscent produced litigation vioxx merck stopped selling clinical trial proved caused heart problems treat different conditions zyprexa vioxx entirely dissimilar thought safer older cheaper drugs becoming bestsellers result turned serious side effects really read full article since i covered evidence surprise company documents made public thank james gottstein evidence mounting time olanzapine risky drug whose small best efficacy advantages offset nasty tendency produce diabetes hat tip furious seasons